A New Leader Takes the Helm at PureTech Health

A New Era for PureTech

PureTech Health has announced the appointment of Robert Lyne as its new CEO. Lyne, who has been serving as the interim CEO since July 2025, brings a wealth of experience to the role. Prior to his interim position, he held the title of Chief Portfolio Officer. His career spans over a decade in life science and venture capital, including a stint as the CEO of Arix Bioscience plc.

Lyne's Vision for PureTech

Lyne is enthusiastic about his new role, highlighting PureTech's strong programs and talented team. His immediate focus is on securing funding for Celea Therapeutics, a new venture within PureTech. A recent meeting with the FDA went smoothly, and the company expects to finalize the deal by the first half of 2026. Once secured, this funding will allow PureTech to reduce its operational expenses.

Strategic Focus on Gallop Oncology

In addition to Celea Therapeutics, Lyne plans to prioritize Gallop Oncology, another key division of PureTech. The program has shown promising data and is advancing to the next stage. Lyne aims to secure funding for this initiative as well. His strategy includes streamlining operations, reducing headcount, and optimizing spending to maximize shareholder value.

Board's Confidence in Lyne

Sharon Barber-Lui, the Interim Chair of the Board, expressed her support for Lyne's appointment. She commended his leadership skills and deep understanding of the business. The Board is confident in his ability to focus on high-priority areas and drive the company forward.

About PureTech Health

PureTech Health is a biotherapeutics company dedicated to developing innovative medicines. With a unique approach to discovery and development, the company has created dozens of therapeutic candidates, three of which have received FDA approval. PureTech's mission is to improve patient outcomes while delivering value to shareholders.